Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer¹

^PrIMFINZI^® (durvalumab) is indicated for the treatment of patients with locally advanced, unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy.

Extensive-Stage Small Cell Lung Cancer¹

Imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

Locally Advanced or Metastatic Biliary Tract Cancer¹

Imfinzi in combination with gemcitabine-based chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer (BTC).

Unresectable Hepatocellular Carcinoma

Imfinzi in combination with tremelimumab is indicated for the first-line treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who require systemic therapy.

• When using Imfinzi in combination with tremelimumab, consult the Product Monograph for IMJUDO (tremelimumab) for further information on this drug.

Imfinzi, as monotherapy, is indicated for the first-line treatment of adult patients with uHCC who require systemic therapy.